DEMOVO® is a concentrated desmopressin oral solution. Sold in a 15millilitre bottle, each millilitre of the solution contains 360 micrograms of anhydrous desmopressin, which is equivalent to 400 micrograms of desmopressin acetate. DEMOVO® is indicated for the treatment of central diabetes insipidus, and the treatment of primary nocturnal enuresis in patients (over 5 years) with normal capacity to concentrate urine.

The dosage of DEMOVO® is individually adjusted in diabetes insipidus patients, but clinical experience has demonstrated that the total daily maintenance dose normally lies in the range of 90-180 micrograms (0.25 – 0.5 ml) three times daily. In primary nocturnal enuresis in adults and children above the age of 5, the appropriate starting dose is 180 micrograms (0.5 ml) of DEMOVO® at bedtime. The dose may be increased up to 360 micrograms (1 ml) if the lower dose is not effective enough.

Treatment periods of three months are recommended. If long-term treatment goes beyond this, a treatment free period of at least one week should be introduced every three months to assess whether spontaneous healing has occurred.

  • One dose presentation
  • Tasteless
  • Colourless
  • Concentrated liquid formulation
  • Low volume
  • No water needed
  • Initiation titration
  • Allows tailored dosing
  • Lowest price
  • No wastage
  • 100% recyclable components

DreamDry® Bedwetting Support App

Developed with support from Bladder & Bowel UK and ERIC, The Children's Bowel & Bladder Charity.

Introducing DreamDry
DEMOVO Abridged Prescribing information
Read now